荣昌生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	1.7B	1.1B	772.0M	1.4B	3.0M
Revenue Growth %	58.5%	40.3%	-45.9%	46741.6%	--
Total Revenue	1.7B	1.1B	772.0M	1.4B	3.0M
Cost Of Revenue	337.0M	244.0M	272.0M	68.8M	2.3M
+Gross Profit	1.4B	839.0M	500.0M	1.4B	737,400
Gross Margin %	80.4%	77.5%	64.8%	95.2%	24.2%
Total Operating Cost	3.2B	2.7B	1.9B	1.2B	770.0M
Selling Expenses	949.0M	775.0M	441.0M	263.0M	24.2M
Admin Expenses	317.0M	304.0M	266.0M	216.0M	213.0M
Rd Expenses	1.5B	1.3B	982.0M	711.0M	466.0M
Finance Expenses	69.5M	-5.4M	-67.9M	-12.3M	61.2M
+Operating Income	-1.5B	-1.5B	-995.0M	303.0M	-704.0M
Operating Margin %	-84.8%	-138.7%	-128.9%	21.2%	-23125.2%
Non Operating Income	398,700	85,300	10.2M	13.1M	8.1M
Non Operating Expenses	13.1M	9.8M	13.8M	39.9M	1.7M
Investment Income	-4.3M	7.0M	12.1M	--	287,500
Fair Value Change Income	1.5M	--	--	--	--
Asset Disposal Income	-704,100	4,200	15,500	1,100	18,600
Asset Impairment Loss	9.6M	12.9M	--	--	--
Other Income	78.8M	65.7M	131.0M	127.0M	62.3M
Income Before Tax	-1.5B	-1.5B	-999.0M	276.0M	-698.0M
+Net Income	-1.5B	-1.5B	-999.0M	276.0M	-698.0M
Net Margin %	-85.5%	-139.5%	-129.4%	19.4%	-22928.1%
Net Income Attributable	-1.5B	-1.5B	-999.0M	276.0M	-698.0M
Eps Basic	-2.73	-2.80	-1.88	0.57	-1.71
Eps Diluted	-2.73	-2.80	-1.88	0.57	-1.71

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	762.0M	743.0M	2.2B	1.8B	2.8B
Accounts Receivable	383.0M	298.0M	202.0M	2.3M	--
Notes Receivable	204.0M	78.7M	--	--	--
Notes And Accounts Receivable	588.0M	376.0M	202.0M	2.3M	--
Prepayments	241.0M	270.0M	199.0M	124.0M	62.0M
Inventory	659.0M	742.0M	523.0M	280.0M	66.2M
Total Current Assets	2.3B	2.2B	3.2B	2.3B	3.0B
Long Term Equity Investment	8.9M	2.7M	1.5M	--	--
Fixed Assets	--	2.0B	1.4B	967.0M	464.0M
Fixed Assets Total	2.5B	2.0B	1.4B	967.0M	464.0M
Construction In Progress	--	796.0M	1.0B	611.0M	339.0M
Construction In Progress Total	283.0M	796.0M	1.0B	611.0M	339.0M
Intangible Assets	143.0M	144.0M	55.9M	52.4M	45.2M
Long Term Deferred Expenses	4.3M	6.8M	5.9M	2.1M	165,000
Total Non Current Assets	3.2B	3.3B	2.8B	1.9B	1.1B
Total Assets	5.5B	5.5B	6.0B	4.2B	4.1B
Short Term Borrowings	1.1B	284.0M	--	--	108.0M
Accounts Payable	162.0M	125.0M	109.0M	36.5M	23.8M
Contract Liabilities	3.1M	11.4M	50,700	27.1M	--
Total Current Liabilities	2.2B	1.1B	877.0M	612.0M	425.0M
Long Term Borrowings	1.2B	841.0M	--	--	--
Total Non Current Liabilities	1.3B	963.0M	164.0M	101.0M	98.0M
Total Liabilities	3.5B	2.1B	1.0B	713.0M	523.0M
Paid In Capital	544.0M	544.0M	544.0M	490.0M	490.0M
Capital Reserve	6.3B	6.2B	6.2B	3.7B	3.7B
Retained Earnings	-4.3B	-2.9B	-1.3B	-343.0M	-620.0M
Equity Attributable	2.0B	3.4B	5.0B	3.4B	3.6B
Total Equity	2.0B	3.4B	5.0B	3.4B	3.6B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	1.5B	889.0M	273.0M	1.4B	445,900
Tax Refunds Received	14.1M	115.0M	179.0M	117.0M	35.5M
Total Operating Cash Inflow	1.6B	1.1B	646.0M	1.7B	98.0M
Cash Paid For Goods	143.0M	297.0M	467.0M	268.0M	17.1M
Cash Paid To Employees	1.1B	995.0M	702.0M	413.0M	206.0M
Taxes Paid	74.3M	21.6M	5.2M	3.4M	3.4M
Total Operating Cash Outflow	2.7B	2.6B	1.9B	1.4B	756.0M
Operating Cash Flow	-1.1B	-1.5B	-1.3B	282.0M	-658.0M
Total Investing Cash Inflow	1.0B	1.2B	1.9B	79.2M	102.0M
Total Investing Cash Outflow	1.3B	2.0B	2.8B	735.0M	583.0M
Investing Cash Flow	-248.0M	-817.0M	-851.0M	-656.0M	-481.0M
Cash From Borrowings	1.8B	1.1B	--	--	760.0M
Dividends And Interest Paid	69.8M	15.4M	--	5.5M	72.1M
Debt Repayments	258.0M	--	--	108.0M	1.3B
Total Financing Cash Inflow	1.8B	1.2B	2.6B	--	5.3B
Total Financing Cash Outflow	413.0M	182.0M	192.0M	627.0M	1.4B
Financing Cash Flow	1.4B	978.0M	2.4B	-627.0M	3.9B
Net Change In Cash	33.0M	-1.3B	312.0M	-1.0B	2.7B
Ending Cash Balance	760.0M	727.0M	2.1B	1.8B	2.8B
Capex	265.0M	853.0M	753.0M	617.0M	481.0M